onr:"swepub:oai:DiVA.org:uu-120547"
Search: onr:"swepub:oai:DiVA.org:uu-120547" > Genotype-guided dos...
- 1 of 1
- Previous record
- Next record
- To hitlist
Genotype-guided dosing of coumarin derivatives : the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design
- van Schie, Rianne M. F. (author)
-
- Wadelius, Mia (author)
- Uppsala universitet,Klinisk farmakogenomik och osteoporos
- Kamali, Farhad (author)
- show more...
- Daly, Ann K. (author)
- Manolopoulos, Vangelis G. (author)
- de Boer, Anthonius (author)
- Barallon, Rita (author)
- Verhoef, Talitha I. (author)
- Kirchheiner, Julia (author)
- Haschke-Becher, Elisabeth (author)
- Briz, Montserrat (author)
- Rosendaal, Frits R. (author)
- Redekop, William K. (author)
- Pirmohamed, Munir (author)
- van der Zee, Anke-Hilse Maitland (author)
- show less...
- (creator_code:org_t)
- Future Medicine Ltd, 2009
- 2009
- English.
- In: Pharmacogenomics (London). - : Future Medicine Ltd. - 1462-2416 .- 1744-8042. ; 10:10, s. 1687-1695
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- The narrow therapeutic range and wide interpatient variability in dose requirement make anticoagulation response to coumarin derivatives unpredictable. As a result, patients require frequent monitoring to avert adverse effects and maintain therapeutic efficacy. Polymorphisms in VKORC1 and CYP2C9 jointly account for about 40% of the interindividual variability in dose requirements. To date, several pharmacogenetic-guided dosing algorithms for coumarin derivatives, predominately for warfarin, have been developed. However, the potential benefit of these dosing algorithms in terms of their safety and clinical utility has not been adequately investigated in randomized settings. The European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) trial will assess, in a single-blinded and randomized controlled trial with a follow-up period of 3 months, the safety and clinical utility of genotype-guided dosing in daily practice for the three main coumarin derivatives used in Europe. The primary outcome measure is the percentage time in the therapeutic range for international normalized ratio. This report describes the design and protocol for the trial.
Keyword
- acenocoumarol
- CYP2C9
- dosing algorithm
- EU-PACT pharmacogenetics
- phenprocoumon
- randomized controlled trial
- VKORC1
- warfarin
- MEDICINE
- MEDICIN
- Clinical Pharmacology
- Klinisk farmakologi
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Pharmacogenomics (London) (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- van Schie, Riann ...
- Wadelius, Mia
- Kamali, Farhad
- Daly, Ann K.
- Manolopoulos, Va ...
- de Boer, Anthoni ...
- show more...
- Barallon, Rita
- Verhoef, Talitha ...
- Kirchheiner, Jul ...
- Haschke-Becher, ...
- Briz, Montserrat
- Rosendaal, Frits ...
- Redekop, William ...
- Pirmohamed, Muni ...
- van der Zee, Ank ...
- show less...
- Articles in the publication
- Pharmacogenomics ...
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
